Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus

 Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus

Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus

Shots:

  • The companies plan to initiate a P-II study assessing selgantolimod + VIR-2218 in treatment-experienced and treatment-naïve people living with HBV. People in the trial with HBV treatment experience may also receive Gilead’s Vemlidy
  • The 1EPs of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of HBsAg and HBV DNA from the serum. The study is the first P-II study that combines immunomodulation and Ag suppression approaches in HBV cure research
  • Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the P-II study

Click here ­to­ read full press release/ article | Ref: Gilead | Image: Revenues & Profits

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post